"Das Institut für Diabetes-Technologie ist ein Forschungsinstitut, spezialisiert auf klinische Forschung im Bereich Diabetes mellitus. Wir führen klinische Studien durch und sind auch auf dem Gebiet der Grundlagenforschung tätig. Die klinischen Studien werden entsprechend der Verordnung (EU) 2017/745 des Europäischen Parlaments und des Rates über Medizinprodukte (MDR), den Vorschriften des Medizinprodukte-Durchführungsgesetz (MPDG), des Medizinproduktegesetzes (MPG) und des Arzneimittelgesetzes (AMG) durchgeführt. Dabei arbeiten wir nach ICH-GCP und unter Beachtung der geltenden nationalen, europäischen und internationalen Vorschriften."

During the past decade, Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" #1 sponsor was "Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" with 13 trials, followed by "RSP Systems A/S" with 4 trials sponsored, "LifeScan Scotland Ltd" with 2 trials sponsored, "Ypsomed AG" with 2 trials sponsored and "B. Braun Melsungen AG" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" #1 collaborator was "Bayer" with 4 trials as a collaborator, "Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" with 3 trials as a collaborator, "Ascensia Diabetes Care" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator and "DCB Research AG" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" are "Diabetes" (11 trials), "Diabetes Mellitus" (7 trials), "Diabetes Mellitus, Type 1" (3 trials), "Assessment of Glucose Concentrations" (1 trials) and "Diabete Mellitus" (1 trials). Many other conditions were trialed in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" in a lesser frequency.

Most popular intervention types in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" are "Device" (22 trials). Other intervention types were less common.

The name of intervention was led by "Blood glucose monitoring systems for self-testing" (3 trials), "Prototype 0.5" (3 trials), "4 blood glucose monitoring systems" (1 trials), "6 blood glucose monitoring systems for self-testing" (1 trials) and "6 blood glucose monitoring systems for self-testing (blood glucose meters)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 21 trials that are defined as “Not Applicable".